A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer (DAPROCA-1)
An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
Sponsor: Aarhus University Hospital
Terminated
A consequence of the results of the ENTHUSE phase III study program
Other terminated trials from Aarhus University Hospital
A PHASE2 clinical study on Metastasis and Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Aarhus University Hospital and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Oct 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aarhus University Hospital
- Rigshospitalet, Denmark
For direct contact, visit the study record on ClinicalTrials.gov .